|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income Loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | ||
| Provision for expected credit losses | ||
| Stock-based compensation expense | ||
| Net provision for excess and obsolete inventory | ||
| Change in fair value of warrant liabilities | ||
| Accretion of discount on short-term investments | ||
| Amortization of premium on long-term investments | ||
| Amortization of operating lease right-of-use asset | ||
| Loss on disposal of property and equipment | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Inventories | ||
| Prepaid expenses and other current assets | ||
| Other long-term assets | ||
| Accounts payable | ||
| Accrued expenses and other current liabilities | ||
| Other long-term liabilities | ||
| Operating lease liability | ||
| Deferred revenue | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities: | ||
| Purchases of short-term investments | ||
| Purchases of long-term investments | ||
| Proceeds from maturities and redemptions of short-term investments | ||
| Proceeds on disposal of property and equipment | ||
| Purchases of property and equipment | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs | ||
| Proceeds from the issuance of common stock from private placement, net of issuance costs | ||
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | ||
| Payments for deferred offering costs | ||
| Proceeds from stock option exercises | ||
| Proceeds from common stock warrants exercise | ||
| Net cash provided by financing activities | ||
| Net increase in cash, cash equivalents and restricted cash | ||
| Cash, cash equivalents and restricted cash at beginning of period | ||
| Cash, cash equivalents and restricted cash at end of period | ||
| Supplemental disclosure of non-cash investing and financing information: | ||
| Purchases of property and equipment included in accounts payable | ||
| Deferred offering costs included in accrued expenses and other current liabilities | ||
| Deferred offering costs included in accounts payable | ||
| Deferred offering costs included in accrued expenses | ||
| Unrealized gain (loss) on short-term investments | ||
| Reclassification of long-term investments to short-term investments | ||
| Conversion of convertible preferred stock upon initial public offering | ||
| Conversion of warrants net exercise upon initial public offering | ||
| Reclassification of deferred offering costs to equity upon initial public offering | ||
| Operating lease right-of-use asset obtained in exchange for operating lease obligations | ||
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | ||
| Restricted cash |
Loading...
